VYNDAQEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYNDAQEL (VYNDAQEL).
Tafamidis is a transthyretin (TTR) stabilizer that binds to TTR, inhibiting the dissociation of the TTR tetramer into monomers, which is the rate-limiting step in the formation of amyloid fibrils. By stabilizing the tetramer, it reduces amyloid deposition in tissues.
| Metabolism | Tafamidis is metabolized via glucuronidation by UGT1A1, UGT1A3, UGT1A4, and UGT2B7. Minor metabolism via CYP3A4 oxidation. Excreted primarily in feces (59%) and urine (22%). |
| Excretion | Primarily excreted unchanged in feces (approximately 70%) via biliary secretion; renal excretion is negligible (<1% of dose). |
| Half-life | Terminal elimination half-life is approximately 25 hours, supporting once-daily dosing with steady-state achieved by 2 weeks. |
| Protein binding | Highly bound (>99%) primarily to albumin, with minor binding to lipoproteins. |
| Volume of Distribution | Approximately 18 L (0.26 L/kg for a 70 kg individual), indicating distribution mainly into plasma and extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 100% (highly absorbed with minimal first-pass metabolism). |
| Onset of Action | Oral: Clinical effects on transthyretin stabilization occur within 2 weeks; maximal reduction in tetramer dissociation by 4 weeks. |
| Duration of Action | Duration of action persists for the dosing interval (24 hours) with sustained transthyretin stabilization; clinical benefits continuous with regular dosing. |
| Molecular Weight | 344.4 |
61 mg orally once daily
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or dialysis. |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not studied in severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Clinical studies included patients aged 65 and older; no overall differences in safety or efficacy observed. |
| 1st trimester | No adequate human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Consider benefits vs risks. |
| 2nd trimester | No adequate human data; animal studies show no fetal harm at clinically relevant doses. Use only if clearly needed. |
| 3rd trimester | No adequate human data; animal studies show no fetal harm at clinically relevant doses. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for VYNDAQEL (VYNDAQEL).
| Placental transfer | Not studied in humans; likely crosses placenta based on molecular weight and lipophilicity. Animal studies show minimal transfer. |
| Breastfeeding | No human data on excretion in breast milk; molecular weight suggests potential for excretion. Advise caution or avoid breastfeeding due to unknown risks to infant. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to tafamidis or any excipients
| Precautions | Monitor serum uric acid levels; tafamidis increases serum uric acid, which may require urate-lowering therapy., Monitor for atrial fibrillation or flutter; cases reported in clinical trials., Monitor for drug interactions with strong CYP3A4 inhibitors/inducers and NSAIDs. |
| Food/Dietary | No specific food interactions are reported. However, since tafamidis is a BCS Class II drug (low solubility, high permeability), it is recommended to take with food to improve absorption. Avoid grapefruit juice as it may inhibit CYP3A4 and increase tafamidis levels, though not contraindicated. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data, caution advised. |
| Teratogenic Risk | Animal studies show developmental toxicity including reduced fetal growth and malformations at exposures below human therapeutic levels. There are no adequate human studies in pregnant women. Risk cannot be excluded in first trimester; potential for fetal harm throughout pregnancy. |
| Fetal Monitoring | Monitor liver function tests (ALT, AST, bilirubin) periodically; thyroid function tests; and for signs of heart failure exacerbation or volume overload. Fetal ultrasound for growth if used during pregnancy. |
| Fertility Effects | Animal studies show reduced fertility and increased preimplantation loss at clinically relevant exposures. Human data are lacking. |
| Clinical Pearls |
| Vyndaqel (tafamidis) is indicated for transthyretin-mediated amyloidosis (ATTR) in adults with cardiomyopathy. It stabilizes transthyretin (TTR), preventing amyloid fibril formation. Monitor liver function tests, as ALT, AST, and bilirubin elevations can occur; discontinue if ALT>3xULN with bilirubin>2xULN. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole) as tafamidis exposure may increase. Dose adjustment not required in mild-moderate hepatic impairment; avoid in severe impairment (Child-Pugh C). |
| Patient Advice | Take Vyndaqel exactly as prescribed; do not change dose or stop without consulting your doctor. · Swallow capsule whole; do not crush, chew, or open. · If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not take two doses at the same time. · Notify your doctor immediately if you experience signs of liver problems: yellowing of skin/eyes, dark urine, abdominal pain, or unexplained fatigue. · Tell your doctor about all medications you take, especially ketoconazole or other azole antifungals. · Do not breastfeed while taking Vyndaqel; discuss contraception if of childbearing potential. |